Carmell Announces $3.0 Million Private Placement

Rhea-AI Summary

Carmell (Nasdaq: CTCX) announces a private placement of 1,333,333 common shares at $2.25 per share, generating $3 million in gross proceeds. CEO participates at $2.88 per share. Brookline Capital Markets acts as placement agent.

Insights

Financial Analyst

The private placement by Carmell Corporation represents a strategic move to raise capital, which could be indicative of the company's growth strategy or a need for additional funds to support ongoing operations and development projects. The issuance of shares at a discount to the CEO is noteworthy, as it suggests a strong belief in the company's future performance from the management's perspective. However, investors should be mindful of potential dilution due to the increase in outstanding shares, which could affect the stock's value.

From a financial standpoint, the $3 million in gross proceeds before expenses is a modest sum, suggesting that this capital raise might be aimed at meeting short-term financial needs rather than funding large-scale expansion or research and development initiatives. The involvement of Brookline Capital Markets as the exclusive placement agent also indicates a targeted approach to reach specific investors, rather than a broad public offering.

Market Research Analyst

Within the bio-aesthetics industry, the demand for products related to skin and hair health is growing, driven by increasing consumer awareness and the desire for personal well-being. Carmell Corporation's decision to raise capital through a private placement could signal plans to capitalize on market trends and invest in product development or market expansion. However, the impact on the stock market will depend on how effectively the company utilizes these funds to generate revenue and improve profitability.

It's also important to consider the broader market conditions and investor sentiment towards the health and wellness sector. If the sector is experiencing positive momentum, Carmell's private placement might be received favorably, potentially leading to a positive impact on its stock performance in the long run.

Securities Legal Expert

The legal aspects of a private placement are important for ensuring compliance with securities regulations. In this case, the participation of the CEO at a higher share price than other investors could raise questions about insider trading regulations; however, it seems to comply with the norms, as it was executed at the closing sale price of the common stock on the Nasdaq Capital Market. This action might be intended to demonstrate confidence to other investors and align the interests of management with those of the shareholders.

Investors should be aware that private placements are typically offered to a select group of accredited investors and are not subject to the same level of public scrutiny as public offerings. This means less information may be available to the public, which could affect the transparency and perceived risk of the investment.

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the “Private Placement”).

The Chief Executive Officer of the Company participated in the Private Placement at a price of $2.88 per common share, which was the closing sale price of its common stock on the Nasdaq Capital Market on April 3, 2024. Following the Closing of the Private Placement, Carmell will have approximately 20.58 million common shares outstanding.

Brookline Capital Markets, a division of Arcadia Securities, LLC, served as the exclusive placement agent for the private placement transaction.

About Carmell
Carmell is a bio-aesthetics company that utilizes the Carmell Secretome^TM to support skin and hair health. The Carmell Secretome^TM consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past 7 years, the Company has extensively tested the technology underpinning the Carmell Secretome^TM. Additionally, the Company has developed a novel microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen^TM, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Carmell’s microemulsion formulations do not utilize mineral or vegetable oils and are designed to be non-comedogenic. The Company is also developing a line of men’s products and a line of topical haircare products. All products are tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. For more information, visit www.carmellcosmetics.com.

About Private Placement
The offer and sale of the shares of common stock to be sold in the Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and other applicable securities laws.
The Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of its common stock sold in the Private Placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the completion of the Private Placement. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, those described under the header “Risk Factors” in the Annual Report on Form 10-K filed by Carmell with the SEC on April 1, 2024, and in our other reports filed with the SEC. Most of these factors are outside of Carmell’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.. Except as required by law, we undertake no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Contact:
Bryan Cassaday
bc@carmellcorp.com

FAQ

What is the ticker symbol for Carmell ?

The ticker symbol for Carmell is CTCX.

How many common shares were issued in the private placement?

Approximately 1,333,333 common shares were issued in the private placement.

What was the price per common share in the private placement?

The price per common share in the private placement was $2.25.

How much gross proceeds were generated from the private placement?

The private placement generated aggregate gross proceeds of $3 million.

Who served as the exclusive placement agent for the private placement transaction?

Brookline Capital Markets, a division of Arcadia Securities, , served as the exclusive placement agent for the private placement transaction.